Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sessler, C. N.
Right arrow Articles by Cooper, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sessler, C. N.
Right arrow Articles by Cooper, K. R.

Chest, Vol 87, 325-329, Copyright © 1985 by American College of Chest Physicians


ARTICLES

Treatment of theophylline toxicity with oral activated charcoal

CN Sessler, FL Glauser and KR Cooper

We treated 14 patients who had an initial serum theophylline concentration greater than 30 micrograms/ml (48.3 +/- 19.4 micrograms/ml) and symptoms of theophylline toxicity with oral activated charcoal (OAC). Thirty-gram doses of OAC were administered approximately every two hours for two to four doses. Ten patients tolerated OAC and demonstrated a reduction in theophylline half-life to 5.6 +/- 2.5 hours with resolution of symptoms. Three of these ten patients were treated in the emergency department and discharged, making hospitalization unnecessary. The four patients with the highest initial theophylline concentrations (76.6 +/- 17.7 micrograms/ml) vomited all doses of OAC. Three of these four patients were treated with charcoal hemoperfusion with a reduction in the half-life to 5.2 +/- 1.0 hours. These data support the use of OAC as the primary therapeutic modality in the management of patients with theophylline toxicity. Patients with very high theophylline concentrations (greater than 50 micrograms/ml), however, usually vomit the OAC and may require charcoal hemoperfusion.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American College of Chest Physicians.